Quanhecheng Completes Over RMB 100 Million Pre-B Financing to Become a Leading Domestic Biotech Service-Oriented Raw Material Supplier

Recently, Tianjin Quanhecheng Technology Co., Ltd. (hereinafter referred to as “Quanhecheng”) announced the successful completion of its Pre-B financing round, exceeding RMB 100 million.This round was exclusively invested by Juneng Venture Capital, with Dianshi Capital serving as the exclusive financial advisor. The new funding will be primarily used for the development and commercial promotion of biotech chemical raw materials and their downstream applications, including nucleic acid drugs, delivery systems, and in vitro diagnostics.

Quanhecheng is committed to becoming the most trusted partner for life sciences enterprises. Adhering to innovation-led development, it actively promotes deep integration among government, industry, academia, and research, expanding the boundaries of both technology and products to form a highly integrated business model. Leveraging years of technological accumulation, Quanhecheng’s major technology platforms are industry leaders in their respective fields. The company has successively established a General Synthetic Technology Platform, a Cross-disciplinary Technology Application Platform, a Gene Therapy Delivery Platform, a Nucleic Acid Drug Discovery Platform, an IVD Technology Service Platform, and an Intellectual Property Operations Platform.

Meanwhile, Quanhecheng has achieved the industrialization of new technologies and fostered a bidirectional synergy between source-level technological innovation to meet industry demands and breakthroughs in areas such as lead compound discovery for nucleic acid drugs, R&D validation, testing platforms, core raw material production, and analytical quality control. Ultimately, it aims to become a leading domestic and world-class supplier of raw materials with biotechnology service capabilities.

Quanhecheng has established a delivery technology platform in the field of gene therapy, aiming to provide customers with comprehensive solutions for targeted drug delivery. In the area of small nucleic acid drug delivery systems, Quanhecheng offers diverse custom synthesis services for GalNAc structures. The company boasts extensive R&D and synthesis experience, the capacity for kilogram-scale delivery, and a rigorous and comprehensive quality control and inspection system. Furthermore, through continuous independent innovation, Quanhecheng has secured multiple patents covering synthetic routes, process optimization, and separation, crystallization, and purification, thereby forming a core patent portfolio that controls key technologies.

Quanhecheng has independently developed an LNP delivery system, addressing the bottleneck of domestic LNP patents and filling a market gap. The company will build a compound library comprising thousands of ionizable cationic lipids, establish design guidelines for cationic lipid structures, and develop a high-throughput in vitro and in vivo evaluation system to resolve issues related to targeting, safety, tolerability, and stability. Focusing on original innovation and breaking through patent barriers, Quanhecheng aims to achieve technological breakthroughs and mass production of multiple core components.

Quanhecheng is one of the leading domestic suppliers of fluorescent probes, having accumulated technical expertise across nearly all major classes of fluorophore scaffolds. With experience in synthesizing over 3,000 fluorescent probe compounds and robust screening capabilities, the company’s products match domestic peers in key quality metrics such as sensitivity, purity, and resistance to background quenching. Its products are widely used in clinical diagnostics and sequencing, drug screening, food, pharmaceutical, and environmental testing, as well as life sciences R&D. As one of the few companies in the industry with simultaneous synthesis capabilities for both fluorescent and nucleoside compounds, Quanhecheng also offers high-purity dNTPs and a series of fluorescently labeled dNTPs tailored for first- and second-generation sequencing, thereby breaking foreign monopolies.

Quanhecheng possesses the capability to develop and manufacture upstream raw materials for the nucleic acid drug industry chain. It provides pharmaceutical companies engaged in nucleic acid drug R&D with key raw materials required for nucleic acid sequence synthesis, including standard and modified phosphoramidite monomers, modified nucleotides, NTPs, cap analogs, and other critical materials, along with customized development services. By addressing bottlenecks that constrain industry development at the source, Quanhecheng ensures the quality stability and production capacity stability of raw materials for nucleic acid drugs.

Leveraging its strengths in aliphatic compound synthesis technology, the company has achieved a doubling of its business growth. With fourteen years of technical expertise in aliphatic synthesis, Quanhecheng has built a portfolio of thousands of innovative products, established technological platforms such as continuous flow and microchannel reactors, and assembled a multidisciplinary team. As a long-term raw material supplier to leading pharmaceutical companies, its technologies and products have gained widespread recognition within the industry.

In 2023, the Tianjin (Economic-Technological Development Area) Nucleic Acid Industry Alliance was established through collaborative efforts among the Tianjin EDA, key universities, state-owned capital platforms, and leading enterprises to build a nucleic acid drug industrial cluster. As one of the founding chair entities, Quanhecheng undertook the operation of the alliance’s intellectual property platform. In the same year, Quanhecheng was approved as the Tianjin Intellectual Property Industry Operation Center (focused on nucleic acid drugs), dedicated to developing IP operations in industries related to cutting-edge nucleic acid drug technologies, thereby accelerating the growth of an IP-driven nucleic acid drug industrial cluster.

Song Yanmin, Founder of QuanhechengStatement: We express our gratitude to Juneng Venture Capital and our existing shareholders for their trust and support. Over the past decade, Quanhecheng has continuously accumulated technological expertise and expanded its business boundaries accordingly, forming a comprehensive business portfolio that includes specialized pharmaceutical intermediates and active pharmaceutical ingredients (APIs), diagnostic analytical chemical raw materials, nucleic acid drug chemical raw materials, and innovative small nucleic acid therapeutics. The company is currently at a historic juncture of opportunity, with robust growth in downstream product applications. Quanhecheng will continue to maintain its leadership in core technologies, intensify the development of cutting-edge raw materials, and establish itself as a leading hub for nucleic acid chemical raw materials.

Ma Lei, General Manager of Juneng Venture CapitalStatement: Molecular biology has driven an explosion of achievements in life sciences research over the past three decades. In recent years, small nucleic acid drugs and mRNA therapeutics have risen rapidly, showing promise to become the third major class of pharmaceuticals. We remain firmly optimistic about the prospects of nucleic acid-based therapies. Quanhecheng boasts over a decade of accumulated technical expertise and a robust product pipeline. Its business has grown steadily, and it has rapidly established a strong foundation of industry clients in recent years, with both its technology and products gaining commercial validation.